艾美疫苗获FDA批准开展mRNA疫苗临床试验
2月27日，艾美疫苗（06660）发布公告，宣布其mRNA呼吸道合胞病毒疫苗已获得美国食品和药品监督管理局（FDA）批准开展临床试验。这是公司首次获得FDA批准进行临床试验，标志着其国际化战略的重要进展。公告中提到，该疫苗在临床前动物试验中，特异性IgG抗体滴度、真病毒中和抗体效价以及特异性T细胞免疫均显著高于国际上市的对照疫苗，显示出其研发成果的竞争力。
呼吸道合胞病毒是导致婴儿和老年人呼吸道感染的重要病原体，目前全球尚无针对该病毒的获批抗病毒特效药，因此接种疫苗成为预防重症感染的有效手段。公司作为中国最早开发mRNA疫苗的企业之一，已建立成熟的研发体系和符合GMP标准的生产车间，能够快速实现疫苗的产业化。随着该疫苗的上市，公司有望迎来新的业绩增长点。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10